Weight LossClinical Trials
Mazdutide
Also known as: LY3305677 · IBI362
A dual GLP-1/glucagon agonist developed in China, achieving 15–18% weight loss that rivals tirzepatide in Phase 3 trials.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
Half-Life
~6–7 days
Typical Dose
6–9 mg weekly
Administration
Subcutaneous injection
Mechanism of Action
Combines GLP-1 appetite suppression with glucagon-mediated thermogenic fat burning for synergistic weight reduction.
Key Research Areas
weight lossGLP-1glucagondual agonist
Frequently Asked Questions
What is Mazdutide?▾
A dual GLP-1/glucagon agonist developed in China, achieving 15–18% weight loss that rivals tirzepatide in Phase 3 trials.
How does Mazdutide work?▾
Combines GLP-1 appetite suppression with glucagon-mediated thermogenic fat burning for synergistic weight reduction.
What is the recommended dosage for Mazdutide?▾
The typical research dosage is 6–9 mg weekly, administered via Subcutaneous injection. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of Mazdutide?▾
The half-life of Mazdutide is approximately ~6–7 days. This affects dosing frequency and timing in research protocols.
Is Mazdutide FDA approved?▾
Mazdutide is currently classified as "Clinical Trials" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.
Research Disclaimer
The information provided about Mazdutide is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.